53324-36-0

Basic information

• Product Name: 5-(4-IODOPHENYL)-1H-TETRAZOLE
• Synonyms: 5-(4-IODOPHENYL)-1H-TETRAZOLE
• CAS NO: 53324-36-0
• Molecular Formula: C₇H₅IN₄
• Molecular Weight: 272.04587
• Mol File: 53324-36-0.mol

Chemical Properties

• Melting Point: 269～271℃(dec)
• Appearance: /
• CAS DataBase Reference: 5-(4-IODOPHENYL)-1H-TETRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-IODOPHENYL)-1H-TETRAZOLE(53324-36-0)
• EPA Substance Registry System: 5-(4-IODOPHENYL)-1H-TETRAZOLE(53324-36-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 53324-36-0(Hazardous Substances Data)

Upstream product

• 3058-39-7 4-iodobenzonitrile 
• 3956-07-8 4-iodobenzamide 

Downstream Products

• 1631160-89-8 5-{4-[2-[3,4,5-tris(octyloxy)phenyl]ethynyl]phenyl}-2H-tetrazole 
• 1631160-90-1 5-[4-(2-{4-[2-[3,4,5-tris(octyloxy)phenyl]ethynyl]phenyl}ethynyl)phenyl]-2H-tetrazole 
• 1631160-87-6 5-[4-(2(p-(hexyloxy)phenyl)ethynyl)phenyl]-2H-tetrazole 
• 1631160-93-4 tris{4-[2-(4-hexyloxyphenyl)ethynyl]phenyl}tris[1,2,4]triazolo[4,3-a:4',3'-c:4'',3''-e][1,3,5]triazine 
• 1631160-88-7 5-{4-[2-(4-didodecylaminophenyl)ethynyl]phenyl}-2H-tetrazole 
• 623907-47-1 2-(chloromethyl)-5-(4-iodophenyl)-1,3,4-oxadiazole 
• 120819-26-3 5-(4-iodo-phenyl)-1-methyl-1H-tetrazole 
• 120819-28-5 5-(4-iodo-phenyl)-2-methyl-2H-tetrazole 

Relevant articles and documents

Synthesis, structure, and antiviral properties of novel 2-adamantyl-5-aryl-2H-tetrazoles

[Figure not available: see fulltext.] The reaction of 5-aryl-NH-tetrazoles with adamantan-1-ol in concentrated sulfuric acid proceeds regioselectively with the formation of the corresponding 2-adamantyl-5-aryl-2H-tetrazoles. Nitration of these compounds l

Donor-acceptor materials exhibiting deep blue emission and thermally activated delayed fluorescence with tris(triazolo)triazine

Five luminescent donor-acceptor compounds based on the tris(triazolo)triazine (TTT) acceptor were prepared. Out of the series of emitters,TTT-3HMATexhibits deep blue emission with CIE(x,y) (0.16, 0.05) and a photoluminescence quantum yield (PLQY) of 0.9

ANTIVIRAL COMPOUNDS AND USE THEREOF

The present invention relates to compounds of formula (I), their use as medicaments, in particular as broad spectrum antiviral agents, their combination with a further antiviral agent and relative pharmaceutical compositions. In particular, the compounds of the invention are useful in the treatment of a disease caused by an enveloped virus.

Arylethynyl-substituted tristriazolotriazines: Synthesis, optical properties, and thermotropic behavior

The synthesis of C3-symmetrical tristriazolotriazines with conjugated arms and lateral alkoxy side chains was performed by a threefold condensation of cyanuric chloride with tetrazoles. Conjugated π segments include phenyl, tolane, and its phenylethynyl-elongated homologue. Disclike and a dendritic molecule have been obtained, and two compounds with a 3,4,5-tris(octyloxy) substitution form broad thermotropic mesophases. The linear optical properties, solvatochromism of the fluorescence, acidochromism, and the two-photon absorption efficiency of selected compounds are reported. Copyright

Iron salts in the catalyzed synthesis of 5-substituted 1H-tetrazoles

A study was conducted to investigate the presence of iron salts in the catalyzed synthesis of 5-substituted 1H-tetrazoles. Para-trifluorotoluonitrile and trimethylsilyl azide were selected as model substrates for the initial metal source screening and the optimization of the reaction conditions. It was observed that the catalysis proceeded successfully producing tetrazole in 91% yield. A screening of various iron salts revealed that both the oxidation state of the iron and the counterion had a minor effect on the catalysis. Iron sources with different purity grades obtained from various providers were applied to investigate that the catalysis was not resulting from trace impurities in the metal salt. It was also observed that the catalysis proceeded successfully for a wide variety of aryl nitriles, providing tetrazoles in high yields. The best catalysis results were achieved with compounds that contained electron-withdrawing groups.

Benzodioxepine derivatives

This invention relates to compounds of the formula wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACCβ inhibitors.

BENZO [b][1,4] DIOXEPINE DERIVATIVES

This invention relates to compounds of the formula (I), wherein B, X, Y, Z, R1 and R2 are as defined in the description, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by ACCβ inhibitors.